Gujarat Terce Labs Q3FY26 Revenue Drops 3% YoY

Gujarat Terce Laboratories reported Q3FY26 revenue of ₹1,229.35 lakhs vs ₹1,268.08 lakhs in Q3FY25, while net profit declined to ₹76.11 lakhs from ₹100.80 lakhs year-on-year.

Gujarat Terce Labs Board Meet Set for Feb 4, 2026

Gujarat Terce Laboratories schedules board meeting on February 4, 2026, to approve Q3FY26 unaudited financial results. Trading window closes from January 1-6, 2026.

Gujarat Terce Labs Files SEBI Disclosure Post Conversion

Gujarat Terce Laboratories files substantial acquisition disclosure under SEBI Regulation 29 following conversion of 3.71 lakh warrants, with promoter holding reaching 17.35% post-acquisition.

Gujarat Terce Laboratories Reports Mixed Q2 Results with Record EBITDA Despite Revenue Decline

Gujarat Terce Laboratories Limited reported quarterly results showing revenue of Rs 1,292.63 lacs compared to Rs 1,330.12 lacs in the previous year, marking a 2.82% decrease. Despite the revenue decline, the company achieved its highest EBITDA performance in history at Rs 194.46 lacs versus Rs 174.21 lacs, representing an 11.62% increase. Net profit decreased by 5.30% to Rs 140.36 lacs from Rs 148.22 lacs. EBITDA margin improved to 15.04% from 13.10%, while PAT margin decreased slightly to 10.86% from 11.14%. The company attributes the revenue reduction to planned scale-down of low-margin factory B2B sales and rationalization of certain non-profitable operations. Management highlighted that the company completed three quarters without external funding, operating through internal accruals and improved cash discipline. The pharmaceutical company operates 8 leading brands across 134 products, with presence in 13 states and 224 districts through 385 stockists and 147 medical representatives.